Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-781 in healthy participants and primary sclerosing cholangitis
NCT07229911Phase 1Recruiting
- Sponsor
- Takeda
- Start
- Jan 2026
- Primary completion
- Apr 2028
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of TAK-781 in Primary Sclerosing Cholangitis (PSC), sponsored by Takeda. Primary endpoints: Treatment-emergent Adverse Events at 32 weeks, Clinically Significant Changes in Clinical Laboratory Values at 32 weeks and 2 more. Started Jan 2026; status: recruiting.
02
Drugs
TAK-781
03
Conditions
Primary Sclerosing Cholangitis (PSC)
Beyond the preview
Go deeper on NCT07229911.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07229911.